Felezonexor free base · Synonyms: CBS9106 | SL801

CBS9106 is a reversible oral inhibitor of CRM1.

For research use only. Not for human or veterinary use.

Target CRM1 Apoptosis

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Felezonexor structure

CAS No.: 1076235-04-5

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 420.00	BP-01842-25mg	In stock	Get quote
50 mg	USD 680.00	BP-01842-50mg	In stock	Get quote
100 mg	USD 1,020.00	BP-01842-100mg	In stock	Get quote
250 mg	USD 1,520.00	BP-01842-250mg	In stock	Get quote
500 mg	USD 2,180.00	BP-01842-500mg	In stock	Get quote
1 g	USD 2,980.00	BP-01842-1g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

CBS9106 (SL-801; Felezonexor) is a reversible oral inhibitor of CRM1 with CRM1 degrading and antitumor activities. CBS9106 arrests the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells.

Biological activity

In Vitro CBS9106 (0.01-10 μM; 72 hours) sensitizes cells to radiation and to suppress the growth of a variety of cancer cell lines. The estimated IC50 values range from 22.3 or 35.6 nM in multiple myeloma (MM).1S or RPMI-8226 cells and from 3 to 278 nM in 60 other human cancer cell lines. CBS9106 (1-400 nM; 24 hours) decreases CRM1 protein expression levels in a dose-dependent manner. In Vivo CBS9106 (31.25-62.5 mg/kg for 5 times weekly, 125 mg/kg for 3 times weekly; p.o.; 2 weeks) significantly suppresses tumor growth at dose levels of 62.5 or 125 mg/kg in mice bearing human MM xenograft models.

Identifiers

SMILES: O=C(C(COCCC(C)(C)C)=C1C)N(NC2=NC(Cl)=C(C(F)(F)F)C=C2)C1=O
InChIKey: CMASLSTVVOYJQY-UHFFFAOYSA-N

Specifications

MW (average): 419.8260
Formula: C₁₈H₂₁ClF₃N₃O₃
CAS No.: 1076235-04-5
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO : 100 mg/mL

Documents

References

[1]. Sakakibara K, Saito N, Sato T, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118(14):3922-3931. doi:10.1182/blood-2011-01-333138

Same target

Search CRM1

Same research area

Search Cancer